BioNTech Net Income From Continuing Ops from 2010 to 2026
| 22UA Stock | EUR 90.20 3.60 3.84% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -386.6 M | Current Value -28.7 M | Quarterly Volatility 1.3 B |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Interest Income of 528.4 M, Interest Expense of 15.2 M or Selling General Administrative of 723.3 M, as well as many indicators such as Price To Sales Ratio of 10.38, Dividend Yield of 0.011 or PTB Ratio of 1.27. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech | Net Income From Continuing Ops |
The Net Income From Continuing Ops trend for BioNTech SE offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether BioNTech is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest BioNTech's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of BioNTech SE over the last few years. It is BioNTech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
BioNTech Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 1,035,301,691 | |
| Coefficient Of Variation | 323.29 | |
| Mean Deviation | 2,077,211,367 | |
| Median | (85,950,000) | |
| Standard Deviation | 3,346,990,513 | |
| Sample Variance | 11202345.5T | |
| Range | 11.1B | |
| R-Value | 0.23 | |
| Mean Square Error | 11340168.1T | |
| R-Squared | 0.05 | |
| Significance | 0.38 | |
| Slope | 149,631,953 | |
| Total Sum of Squares | 179237527.9T |
BioNTech Net Income From Continuing Ops History
About BioNTech Financial Statements
BioNTech stakeholders use historical fundamental indicators, such as BioNTech's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although BioNTech investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioNTech's assets and liabilities are reflected in the revenues and expenses on BioNTech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioNTech SE. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -765.1 M | -726.8 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of BioNTech Correlation against competitors. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.